BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc.
770 Lindaro Street
San Rafael, CA 94901
Phone: (415) 506-6700Website: https://www.biomarin.com/Careers: careers.biomarin.com
Latest news
- BioMarin Announces Advancements in FDA Review of ROCTAVIAN for Adults with Severe Hemophilia A
24 November 2022 - BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
29 September 2022 - FDA Approves Voxzogo (vosoritide) to Increase Linear Growth in Children with Achondroplasia
19 November 2021 - BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
20 March 2021 - BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
8 March 2021 - FDA Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia
2 November 2020 - BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia
20 August 2020 - BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
19 August 2020 - BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
17 June 2020 - BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
31 May 2020
Drugs Associated with BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. manufactures, markets and/or distributes more than 7 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Aldurazyme
Generic name: laronidase Drug class: lysosomal enzymes |
||
|
Brineura
Generic name: cerliponase alfa Drug class: lysosomal enzymes |
||
|
Kuvan
Generic name: sapropterin Drug class: miscellaneous metabolic agents |
||
|
Naglazyme
Generic name: galsulfase Drug class: lysosomal enzymes |
||
|
Palynziq
Generic name: pegvaliase Drug class: miscellaneous metabolic agents |
||
|
Vimizim
Generic name: elosulfase alfa Drug class: lysosomal enzymes |
||
|
Voxzogo
Generic name: vosoritide Drug class: miscellaneous hormones |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
